Click on the links below to view completed TRND projects:
- Aes-103 for Sickle Cell Disease
- Antifibrotic Therapy for the Treatment of Pulmonary Hypertension
- Auranofin for Chronic Lymphocytic Leukemia
- AVI-4038 for Treatment of Duchenne Muscular Dystrophy
- Bone Morphogenetic Protein Inhibitors to Treat Fibrodysplasia Ossificans Progressiva
- CMX001 for Treatment of Neonatal Herpes Simplex Virus
- Cyclodextrin for Niemann-Pick Type C1 Disease
- Deuterated Analogs of Praziquantel for Treatment of Schistosomiasis
- Development of a Therapeutic for Lassa Fever
- Development of Acoziborole for the Treatment of Human African Trypanosomiasis
- Development of Oxadiazoles as Treatment for Schistosomiasis and Hookworm
- Development of the Novel Antifungal VT-1129 for Cryptococcal Meningitis
- Development of VBP15 for Treatment of Duchenne Muscular Dystrophy
- DEX-M74 for GNE Myopathy (Hereditary Inclusion Body Myopathy)
- Gene Therapy for the Treatment of AADC Deficiency
- Gene Therapy for the Treatment of Pompe Disease
- Inhaled GM-CSF Therapy for Autoimmune Pulmonary Alveolar Proteinosis
- LUM-001 as a Treatment for Creatine Transporter Deficiency
- Novel Treatment for Hermansky-Pudlak Syndrome Pulmonary Fibrosis
- PAK Inhibitor for Fragile X Syndrome
- A Protein Replacement Drug for Friedreich’s Ataxia
- Repurposing an EU Therapeutic for Hemoglobinopathies
- Small Molecule Pharmacological Chaperone for the Treatment of Autosomal Dominant Retinitis Pigmentosa
- Therapy for Fuchs Endothelial Corneal Dystrophy
- Treatment of Acid Ceramidase Deficiency
- Use of Rapamycin for the Treatment of Hypertrophic Cardiomyopathy in Patients with Noonan Syndrome with Multiple Lentigines (NSML)
- Use of Retinal Progenitor Cells for the Treatment of Retinitis Pigmentosa
